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Abstract	
	
Epidemiology	and	the	results	of	large-scale	outcome	trials	indicate	that	the	association	of	
LDL	with	atherosclerotic	cardiovascular	disease	is	causal,	and	continuous	not	only	across	
levels	seen	in	the	general	population	but	also	down	to	sub-physiological	values.	There	is	no	
scientific	basis,	therefore,	to	set	a	target	or	‘floor’	for	LDL	cholesterol	lowering,	and	this	
presents	a	clinical	and	conceptual	dilemma	for	prescribers,	patients	and	payers.	With	the	
advent	of	powerful	agents	such	as	proprotein	convertase/subtilisin	kexin	type	9	(PCSK9)	
inhibitors,	LDL	cholesterol	can	be	lowered	profoundly	but	health	economic	constraints	
mandate	that	this	therapeutic	approach	needs	to	be	selective.	Based	on	the	need	to	
maximise	the	absolute	risk	reduction	when	prescribing	combination	lipid-lowering	therapy,	
it	is	appropriate	to	prioritise	patients	with	the	highest	risk	(aggressive,	established	CVD)	who	
will	obtain	the	highest	benefit,	that	is,	those	with	elevated	LDL	cholesterol	on	optimized	
statin	therapy.	 	
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Introduction	
Few	topics	currently	provoke	as	much	heated	debate	-	both	in	the	scientific	literature	and	lay	press	–	
as	the	use	of	cholesterol	lowering	therapies	to	prevent	cardiovascular	disease	(CVD).	Reviews,	
editorials	and	guidelines	provide	enthusiastic	endorsement	of	ever	more	aggressive	goals	for	
therapy	(1-4),	or	caution	lest	there	is	a	drive	to	overtreatment	with	insufficient	attention	paid	to	risk	
of	side	effects	and	tolerability	(5,6),	and,	of	course,	cost-effectiveness	(7,8).	In	the	pre-statin	era,	this	
was	not	an	issue	since	medications	had	limited	efficacy.	Following	the	unequivocal	trial	evidence	
that	LDL	cholesterol	(LDLc)	lowering	with	statins	was	beneficial	in	both	primary	and	secondary	
prevention	(3,4,9),	there	was	widespread	acceptance	of	this	treatment	approach	but	concerns	raised	
over	tolerability	especially	in	primary	prevention	(6,10),	and	the	medicalization	of	what	was	seen,	at	
least	in	asymptomatic	individuals,	as	a	lifestyle	issue.	It	is	the	demonstration	of	the	success	of	
combined	lipid	lowering	treatments	with	ezetimibe	(11)	and,	particularly,	proprotein	
convertase/subtilisin	kexin	9	(PCSK9)	inhibitors	(12)	that	has	sharpened	the	debate	since	it	is	now	
possible	to	achieve	previously	unheralded	LDLc	levels,	well	below	the	recommended	targets	of	70	to	
100	mg/dl	advocated	for	example	in	Europe	(4).	How	low	do	you	go?	What	are	the	benefit:	risk	and	
benefit:	cost/opportunity	ratios?	Which	patients	should	be	prioritised	for	intensive	LDLc	lowering	
treatment?	The	following	discussion	sets	out	the	conceptual	framework	for	optimised	LDLc	lowering,	
summarizes	the	clinical	trial	evidence	for	combined	lipid	lowering	therapy,	and	offers	therapeutic	
strategies	that	may	aid	in	the	appropriate	use	of	newly	marketed	and	emerging	drugs	such	as	PCSK9	
inhibitors,	cholesteryl	ester	transfer	protein	(CETP)	inhibitors,	and	small	RNA-	or	anti-sense	
oligonucleotide-based	therapies	(13).	
	
Context	and	therapeutic	rationale	for	LDL	cholesterol	lowering.	
	
Underpinning	the	rationale	for	ever	more	aggressive	LDLc	lowering	in	the	prevention	of	the	first	or	
recurrent	major	cardiovascular	events	is	our	understanding	of	the	relationship	between	plasma	
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cholesterol	(mainly	carried	in	LDL)	and	atherosclerosis,	the	silent	disease	process	that	leads	to	
clinical	manifestations	of	MI	and	ischemic	stroke.	Cholesterol	is	one	of	the	major	risk	factors	
alongside	raised	blood	pressure,	smoking,	and	diabetes.	Consideration	of	the	totality	of	the	evidence	
has	led	an	international	expert	panel	to	conclude	that	LDL	is	a	(the?)	major	causal	agent	in	the	
pathogenesis	of	the	disease	(14)	and	differs	conceptually	from	others	such	as	smoking	and	high	
blood	pressure	which	can	be	viewed	as	aggravating	factors	that	accelerate	plaque	progression	once	
lesion	formation	is	initiated.	Evidence	to	support	this	view	comes	from	epidemiological	
investigations	where	populations	with	lifelong	low	cholesterol	levels	have	virtually	no	CVD	despite	
having	an	elevated	inflammatory	state	(14,	15).	Likewise,	experiments	of	nature	–	inherited	
conditions	of	low	and	high	LDLc	-	reveal	reduced	or	elevated	incidence	of	CVD	independent	of	the	
presence	or	absence	of	other	risk	factors.	Homozygotes	for	PCSK9	loss-of-function	mutations	have	
substantially	lower	lifetime	LDLc	levels	and	a	much-reduced	risk	for	CVD	(16),	while	individuals	with	
familial	hypercholesterolemia	(FH)	have	raised	LDLc	from	birth	and,	if	untreated,	suffer	a	MI	typically	
in	mid-life	if	heterozygous,	and	in	childhood	if	homozygotes	(17,18).	Should	we	therefore	consider	
LDLc	as	a	risk	factor	that	is	best	minimised	(perhaps	not	to	zero)	in	analogy	with	the	promotion	of	
smoking	abstinence,	rather	than	a	physiological	parameter	that	needs	to	be	maintained	in	an	
optimal	range,	like	blood	pressure	or	blood	glucose?	
	
Figure	1	provides	a	conceptual	framework	in	which	we	can	understand	the	impact	of	LDL	on	
atherosclerosis,	the	opportunities	for	intervention	at	various	stages	of	the	disease,	and	the	rationale	
for	profound	cholesterol	lowering.	In	considering	the	potential	consequences	of	reducing	LDLc	
substantially,	it	should	be	borne	in	mind	that	as	children	we	had	a	low	LDLc;	the	mean	was	about	95	
mg/dl	and	the	5th	percentile	about	65	mg/dl	(19).	These	levels,	analogous	to	those	in	primates	(14),	
saw	us	through	the	developmental	challenges	of	puberty,	and	a	pharmacological	return	to	such	
values	should	not	of	itself	be	problematic.	LDLc	rises	substantially	in	men	from	late	teens	to	mid-life	
(Figure	1)	(19),	probably	due	to	a	reduction	in	the	activity	of	LDL	receptors	with	ageing	(20).	It	is	this	
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change	in	LDLc	that	likely	drives	atherogenesis	(a	similar	rise	occurs	in	women	after	the	menopause).	
Further,	an	emerging	concept,	based	on	the	early	CVD	seen	in	FH		(Figure	1)	(14,18),	is	that	what	
matters	most	is	the	integrated	length	of	exposure	to	elevated	levels	i.e.	accumulated	‘LDLc	x	years’.		
	
Genetic	analysis	has	provided	additional	insight	into	the	potential	effectiveness	of	LDLc	lowering.	
Mendelian	randomisation	studies	based	on	moderate-effect	variants	that	alter	LDLc	levels	(14,21,22)	
have	successfully	predicted	the	outcome	of	clinical	trials,	and	reveal	that	the	benefit	of	reducing	
LDLc	by	a	given	amount	over	a	lifetime	far	exceeds	that	seen	when	the	lipoprotein	is	decreased	
using	drugs	in	clinical	trials	at,	on	average,	about	62	years	of	age;	for	example	the	relative	risk	
reduction	for	a	39mg/dl	lower	LDLc	from	birth	is	estimated	at	54%	compared	to	the	22%	seen	from	
meta-regression	of	statin	treatment	trials	of	5	years	duration	(21).	Put	another	way,	in	order	to	
achieve	a	50%	risk	reduction	LDLc	needs	to	be	decreased	by	about	35mg/dl	if	treatment	is	initiated	
in	early	adulthood	but	by	100mg/dl	if	started	late	in	life	(Figure	1).	This	differential	may	be	explained	
by	the	changing	nature	of	the	lesions	with	age.	Resolution	of	early	plaque/	fatty	streaks	may	be	
more	easily	achieved	with	moderate	LDLc	lowering	while	much	more	aggressive	treatment	is	needed	
to	stabilise	and	regress	mature,	vulnerable	lesions	seen	later	in	life.	
	
Clinical	trial	evidence	for	the	benefits	of	profound	LDL	cholesterol	lowering.	
	
The	first	landmark	LDLc	lowering	trials	in	secondary	prevention	(4S	with	20-40mg	simvastatin;	(23))	
and	primary	prevention	(WOSCOPS	with	40mg	pravastatin;	(24))	used	what	is	now	considered	
‘moderate	intensity’	statin	therapy	that	reduced	CVD	risk	by	about	one-third.	The	benefit	of	higher	
statin	doses	was	subsequently	examined	in	a	series	of	studies,	most	notably	PROVE-IT	(25)	and	
Treat-To-New-Targets	(TNT	(26))	and	this	led	to	the	recommendation	that	‘high	intensity’	treatment	
be	used	in	high-risk	individuals	with	established	CVD	(3,4).	Figure	2A	(adapted	from	(14))	
summarises	the	outcome	of	clinical	trials	of	LDLc	lowering	in	primary	and	secondary	prevention	
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settings.	It	can	be	seen	that	there	is	a	convincing	continuous	relationship	between	achieved	LDLc	
level	in	the	two	arms	of	a	study	(placebo	vs	active	drug,	or	higher	vs	lower	statin	dose)	and	risk	of	a	
major	coronary	event.	In	European	and	Canadian	guidelines,	this	evidence	base	was	interpreted	to	
indicate	that	‘lower	is	better’	and	more	aggressive	LDLc	targets	were	promulgated	for	high	risk-
primary	and	secondary	prevention	(4,27).	Controversially	in	the	most	recent	revision,	US	guidelines	
emphasised	treating	patient	groups	aligned	with	those	tested	in	the	landmark	trials	rather	than	
focussing	on	achievement	of	goals	(3).	While	this	approach	has	merits,	there	have	been	calls	for	the	
reinstatement	of	targets	especially	with	the	introduction	of	effective	add-on	therapies	(28).	
	
Following	years	of	‘negative’	trials	examining	mainly	the	potential	benefits	of	raising	HDL	to	address	
the	residual	risk	in	patients	on	optimised	statin	therapy	(29,30),	there	has	been	recently	notable	
success	in	demonstrating	incremental	risk	reduction	from	further	LDLc	lowering	using	combination	
therapy	with	a	cholesterol	absorption	inhibitor	(ezetimibe),	or	a	PCSK9	inhibitor	(such	as	
evolocumab).	IMPROVE-IT	was	the	first	of	the	successful	combined	lipid	lowering	trials	to	report	
(11).	It	showed	that	in	well-treated	subjects	on	statin	therapy,	addition	of	ezetimibe	led	to	a	further	
decrement	in	LDLc	–	from	a	mean	of	74mg/dl	to	63mg/dl	(with	38%	achieving	LDL	cholesterol	levels	
<	50	mg/dl	(31))	–	and	a	decrease	in	CVD	risk	of	6.4%	(P=0.016).	This	was	the	first	demonstration	
that	a	non-statin	drug	could	reduce	risk	significantly	and	so	reinforced	the	causal	association	of	LDL	
with	CHD	(14)	that	had	been	questioned	on	the	basis	of	the	repeated	observation	that	only	statins	
appeared	to	be	able	to	decrease	risk	(32).	There	were	no	safety	signals	of	concern	in	the	trial	
comparing	the	two	treatment	arms	(11),	and	when	all	subjects	were	grouped	together	and	LDLc	
across	the	range	of	<30	to	>70	mg/dl	related	to	a	range	of	emergent	adverse	events	over	the	trial	
period,	there	were	again	no	signals	that	very	low	LDLc	was	linked	to	a	higher	frequency	of	adverse	
events	(31).	The	investigators	paid	particular	attention	to	non-cardiovascular	death,	haemorrhagic	
stroke,	and	neurocognitive	events,	all	of	which	had	been	raised	as	potential	issues.	An	association	of	
cancer	with	lower	cholesterol	was	observed	but	this	can	be	attributed	to	the	inclusion	of	the	placebo	
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group	and	the	known	relationship	in	the	general	population	that	is	understood	not	to	be	cause	and	
effect	(i.e.	people	with	cancer	develop	low	cholesterol	levels	rather	than	vice	versa).	This	analysis	in	
very	low	LDLc	subjects	mirrors	the	more	comprehensive	evaluation	that	was	generated	using	meta-
analysis	of	lipid-lowering	trials	(33).	
	
The	eagerly	awaited	FOURIER	trial	(12)	was	the	first	large-scale	test	of	the	ability	of	PCSK9	inhibitors	
to	reduce	CVD	risk.	Change	in	LDLc	was	dramatic,	from	a	mean	of	92mg/dl	to	30mg/dl;	patients	in	
this	trial	had	the	lowest	levels	of	LDLc	yet	achieved	with	pharmacological	intervention.	Incidence	of	
the	primary	endpoint	was	15%	lower	(P<0.001),	and	the	key	secondary	endpoint	20%	lower,	in	the	
PCSK9	inhibitor	treated	group	versus	those	receiving	placebo.	As	with	IMPROVE-IT,	the	clinical	
benefit	was	seen	on	a	background	of	statin	therapy	(69.5%	were	on	‘high’	and	30.2%	on	‘moderate’	
intensity	statin	regimes).	The	trial	has	been	criticised	due	to	its	short	duration	and	lack	of	
demonstration	of	an	effect	on	cardiovascular	mortality	(likely	linked	features)	but	over	the	mean	2.2	
years	of	follow	up	there	were	no	treatment-emergent	safety	signals.	A	concern	about	neuro-
cognitive	side	effects	that	had	arisen	from	phase	3	trials	of	PCSK9	inhibitors	(34,35)	was	addressed	in	
the	EBBINGHAUS	sub-study	(36)	where	a	battery	of	cognitive	assessments	was	undertaken	and	the	
results	for	subjects	on	evolocumab	found	to	be	essentially	identical	to	those	on	placebo.	The	
FOURIER	investigators	embarked	on	an	exploration	of	the	clinical	consequences	of	inducing	
profoundly	low	LDLc	levels	using	the	whole	trial	data	set	in	an	approach	(37)	that	mirrored	that	
described	above	for	IMPROVE-IT	(31).	When	achieved	LDLc	for	the	combined	treatment	groups	was	
related	to	risk	of	cardiovascular	endpoints,	it	was	seen	that	there	was	no	lower	limit	of	efficacy;	
rather,	there	was	a	continuous	relationship	with	a	monotonic	decrease	in	incidence	of	CVD	from	the	
group	with	highest	LDLc	(>100mg/dl)	to	that	with	the	lowest	(<20mg/dl)	(Figure	2B).	Even	going	
below	10mg/dl	appeared	to	give	further	benefit	(37).	A	range	of	safety	concerns	was	addressed	-	
including	liver	dysfunction,	creatine	kinase	levels,	worsening	of	diabetes	control,	cataracts,	
haemorrhagic	stroke,	cognition,	and	cancer	–	and	there	was	no	discernible	adverse	trend	with	even	
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very	low	LDLc.	In	a	further,	detailed	analysis	of	the	recognised	link	between	LDLc	lowering	and	
increased	risk	of	developing	diabetes	(38),	it	was	seen	in	FOURIER	that	evolocumab	therapy	on-top	
of	statin	over	the	period	of	the	study	did	not	increase	the	incidence	of	type	2	diabetes	in	the	whole	
cohort	or	those	with	pre-diabetes,	nor	did	it	appear	to	worsen	glycaemic	control	in	subjects	with	
diabetes	at	baseline	(39).	This	observation	contrasts	with	findings	from	Mendelian	randomisation	
studies	which	showed	that	having	a	lower	LDLc	associated	with	PCSK9	variants	was	linked	to	
increased	risk	of	diabetes	in	a	manner	similar	to	that	seen	for	variation	in	the	gene	for	3-hydroxy-3-
methyl-glutaryl	co-enzyme	A	(mimicking	statin	therapy)	(40).	This	discordancy	between	genotypic-	
and		clinical	trial	–	findings	reflects	the	strengths	and	weaknesses	of	each	approach	to	determining	
the	benefits	and	disadvantages	on	an	intervention	(see	(41)	for	a	review).	As	noted,	the	duration	of	
FOURIER	at	just	over	2	years	limits	the	ability	to	detect	late-appearing	treatment-emergent	side	
effects,	and	the	genetic	observations	leave	the	diabetes	link	an	open	question.		
	
The	results	of	IMPROVE-IT	and	FOURIER,	together	with	the	more	comprehensive	evaluation	from	
meta-regression	(33)	provide	strong	evidence	that	there	is	no	discernible	‘floor’	to	the	association	of	
LDL	with	CVD	risk,	and	so	far,	no	safety	concern	over	inducing	profoundly	low	levels	of	this	
lipoprotein.	The	editorial	accompanying	the	FOURIER	low	LDLc	analysis	talked	of	moving	from	
targets	to	the	concept	of	LDL	‘eradication’	(1).	
	
Pooled	findings	from	phase	3	studies	with	alirocumab	(34,	42)	have	revealed	that,	as	for	
evolocumab,	in	subjects	with	profoundly	lowered	LDLc	(<15mg/dl	and	<25mg/dl)	there	appears	to	
be	little	of	concern	regarding	safety,	although	again	duration	of	exposure	and	the	numbers	of	
patients	treated	render	these	preliminary	conclusions.	There	was	an	imbalance	in	cataract	frequency	
(42)	that	in	theory	could	have	a	basis	in	altered	cholesterol	metabolism	in	the	eye	since	cholesterol	
is	an	important	structural	component	of	the	lens	(43)	and	in	theory	its	availability	may	be	
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compromised	when	LDLc	levels	are	very	low.	This	observation	needs	to	be	confirmed	or	refuted	in	
the	major	ODYSSEY	OUTCOMES	trial	(44).	
	
Of	especial	importance	for	both	IMPROVE-IT	and	FOURIER	was	the	finding	that	the	relationship	
between	change	in	LDLc	and	reduction	in	CHD	risk	fell	on	the	same	regression	line	as	that	generated	
by	meta-analysis	of	all	the	statin	based	studies	(9,11,12,45).	The	Cholesterol	Treatment	Trialists	
Collaboration	(CTTC)	analysis	showed	that	for	each	39mg/dl	(1.0mmol/l)	lower	LDLc	there	is	a	22%	
decrease	in	CHD	risk	over	a	5-year	exposure	to	drug	therapy	(9).	Ezetimibe	treatment	gave	an	
11mg/dl	drop	in	LDLc	and	a	proportionate	6.5%	decrease	in	risk	in	the	7-year	trial	(11).	For	FOURIER,	
it	is	necessary	due	to	the	short	follow	up	to	take	account	of	the	fact	that	only	half	the	risk	reduction	
is	seen	in	year	1	and	correcting	for	trial	length	showed	that	the	PCSK9	inhibitor	yielded	the	predicted	
magnitude	of	benefit	(12,45).	
	
Direct	assessment	of	the	extent	of	atherosclerosis	and	its	relationship	to	LDLc	has	been	examined	in	
imaging	trials	where	lipid	lowering	interventions	have	been	shown	to	slow	progression,	and	induce	
regression,	of	atherosclerotic	lesions	(46).	The	finding	that	regression	occurs	in	the	majority	of	
patients	who	achieve	very	low	LDLc	levels	in	the	GLAGOV	trial	of	evolocumab	treatment	(47)	
reinforces	the	view	that	the	association	of	this	lipoprotein	with	the	underlying	disease	process	is	
causal,	and	further	demonstrates	that	plaque	is	amenable	to	considerable	remodelling,	with	
resultant	beneficial	effects	on	clinical	outcomes.	
	
The	latest	lipid	lowering	add-on	outcome	trial	to	show	a	significant	(but	modest)	CVD	benefit	was	
the	HPS-REVEAL	study	with	anacetrapib	(48),	a	drug	designed	to	raise	HDL	(which	it	doubles)	but	
that	also	reduces	LDLc	by	30%	to	40%	(48).	The	trial	was	powered	to	see	an	effect	of	LDLc	lowering	
in	contrast	to	earlier	cholesteryl	ester	transfer	protein	(CETP)	inhibitor	studies	that	were	smaller	and	
of	shorter	duration	(e.g	30).	Anacetrapib	on	top	of	optimised	statin	therapy	in	subjects	with	already	
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low	LDLc	(baseline	LDLc	was	63mg/dl)	gave	a	9%	risk	reduction	for	a	further	29mg/dl	decrease	in	
LDLc	and	a	18mg/dl	drop	in	non-HDL	cholesterol	and	in	apolipoprotein	B	(apoB)	(48).	This	agent	has	
been	shown	to	alter	the	ratio	of	cholesterol	to	protein	in	lipoprotein	particles,	which	makes	accurate	
measurement	of	LDLc	problematic	(49).	A	better	guide	to	efficacy	in	these	circumstances	is	likely	to	
be	change	in	apoB,	the	structural	protein	in	atherogenic	lipoproteins	(49,50).	(Note	that	the	
manufacturer	has	decided	not	to	apply	for	registration	of	anacetrapib	due	to	issues	associated	with	
the	properties	of	the	agent	–	a	particular	concern	was	the	substantial	accumulation	of	the	drug	in	
adipose	tissue	(48)	-	and	it	is	not	yet	clear	if	there	will	be	further	development	of	the	CETP	inhibitor	
class).	A	concomitantly	reported	Mendelian	Randomisation	‘trial’	–	confirmed	the	concept	that	CETP	
inhibition	combined	with	statin	therapy	was	likely	to	reduce	CVD	risk,	and	again	the	benefit	was	
predicted	to	be	proportional	to	the	decrease	in	apoB	(LDL	particle	number)	not	LDL	cholesterol	(51),	
an	important	finding	when	considering	initiating	and	monitoring	aggressive	cholesterol	lowering	
therapy.	
	
There	are	potential	concerns	about	very	low	LDLc	levels	based	on	observations	in	the	human	
disorders	of	abetalipoproteinemia	and	homozygous	hypobetalipoproteinemia	(52).	Here	LDLc	and	
apoB	are	<30	mg/dl	(or	zero)	and	symptoms	appear	associated	with	failure	to	transport	fat	soluble	
vitamins	and	with	development	of	a	fatty	liver.	In	this	context,	it	is	critical	to	note	that	the	
mechanism	of	LDLc	lowering	differs	between	these	deficiency	states	and	the	actions	of	statins,	
ezetimibe	and	PCSK9	inhibitors.	In	abetalipoproteinemia	and	homozygous	hypobetalipoproteinemia,	
there	is	defective	lipoprotein	production	in	liver	and	gut	(52).	Statins	by	reducing	intracellular	
cholesterol	levels	induce	expression	of	LDL	receptors	and	so	accelerate	clearance	of	LDL	from	the	
circulation	(14,53),	similarly	ezetimibe	reduces	cholesterol	absorption	and	transport	to	the	liver	and	
thereby	increases	LDL	particle	clearance	(14,53).	PCSK9	inhibitors	promote	clearance	of	LDL	and	
other	apoB-containing	lipoproteins	from	the	bloodstream	by	blocking	the	action	of	PCSK9	on	LDL	
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receptors	(54).	None	of	the	three	drug	classes	appear	to	alter	lipoprotein	production	rates	(14,54),	
and	so	transport	of	fatty	substances	is	likely	therefore	be	preserved	with	these	agents.	
	
	
Treatment	strategies	to	achieve	very	low	LDL	cholesterol.	
	
In	light	of	the	latest	evidence	from	trials	exploring	the	benefits	and	risks	of	profound	LDLc	lowering	
the	answer	to	the	question	‘How	low	do	you	go?’	is,	arguably,	a	straightforward	‘As	low	as	you	can!	
There	is,	of	course,	the	need	for	much	longer	follow	up	data	for	PCSK9	inhibitor	trials,	as	is	now	
available	for	statin	studies	(55).	There	are	also	measurement	issues	that	are	reviewed	below	since	
they	impact	on	clinical	practice	(56),	and	cost-effectiveness	concerns	since	PCSK9	inhibitors	are	
expensive.	
	
Figure	3	summarizes	current	thinking	on	the	deployment	of	combination	therapy	to	achieve	lower	
LDLc	levels.	While	guidelines	advocate	the	use	of	high	intensity	statin	treatment	in	high	risk	settings	
such	as	secondary	prevention,	it	should	be	noted	that	the	‘rule	of	6%’	applies	in	that	doubling	the	
statin	dose	will	on	average	lower	LDLc	only	by	this	amount	(3,4,57);	dose-response	studies	have	
shown	consistently	that	each	statin	has	a	characteristic	response	at	the	starting	dose	e.g	37%	LDLc	
lowering	on	10mg	of	atorvastatin	and	that	up-titration	to	a	20mg	or	40mg	dose	produces	a	LDLc	
reduction	of	43%	and	48%	respectively	(57).		This	limitation	on	the	action	of	statins	is	due,	it	is	
believed,	to	the	counter-regulatory	increase	in	PCSK9	induced	by	these	drugs	which	has	the	effect	of	
blunting	the	increase	in	LDL	receptors	and	hence	limiting	LDLc	reduction	(58).	International	surveys	
reveal	that	while	use	of	high	intensity	statin	therapy	is	a	recommended	evidence-based	approach,	it	
is	not	sustained	in	regular	clinical	practice	(59).	Further,	statins,	though	strongly	recommended	as	
first	line	therapy	for	lipid	lowering	have	a	well-characterised	set	of	side-effects	including	increased	
propensity	to	develop	diabetes	especially	in	patients	with	pre-diabetes	or	known	risk	factors	for	
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diabetes	(3,4,33,38).	Statin	intolerance	is	also	a	recognised	phenomenon	and	is	often	linked	to	
myalgia	and	other	muscle-related	symptoms	(33,60).	These	adverse	reactions	are	dose	dependent	
and	can	be	a	reason	why	‘high	intensity’	statin	therapy	recommended	in	the	guidelines	is	not	always	
used	in	practice.	Combination	therapy	now	tested	in	multiple	clinical	trials	offers	an	effective	
alternative	with	potentially	improved	patient	acceptance,	and	enhanced	efficacy.	
	
A	number	of	reports	have	appeared	on	the	health	economics	of	combination	lipid	lowering	therapy	
to	achieve	low	or	very	low	LDLc	levels.	There	is	general	agreement	that	with	the	increased	
availability	of	generic	ezetimibe,	addition	of	this	agent	offers	a	cost-effective	approach	to	lowering	
LDLc	beyond	what	can	be	achieved	with	statins	(61).	Marketed	PCSK9	inhibitors,	however,	cost	
about	$14,000	per	year	in	the	USA,	and	about	€4,500	in	Europe,	and	despite	their	considerable	
impact	on	LDLc	are	considered	acceptable	in	terms	of	cost	per	quality-adjusted	life	year	(QALY)	only	
when	there	is	a	substantial	discount,	i.e.	to	a	price	of	about	$9,000	per	annum	in	the	USA	or	less	
than	£4,500	in	the	UK	(62-65).	In	this	context,	the	economics	of	CVD	prevention	is	linked	directly	to	
the	number	of	events	prevented,	the	frequency	of	treatment-emergent	side	effects,	as	well	as	the	
price	of	the	medication.	To	maximise	event	reduction	and	so	minimise	the	cost	per	QALY,	it	is	
important	to	understand	that	the	absolute	risk	reduction	(number	of	events	prevented	over	a	given	
time)	is	considered	by	many	commentators	to	be	the	key	metric	in	deciding	when	profound	LDLc	
lowering	with	combination	therapy	should	be	used	(64-67).	This	parameter	is	estimated	as	the	
product	of	the	patient’s	ongoing	risk	of	a	CVD	event	and	the	relative	risk	reduction	attributable	to	
further	LDLc	lowering.	The	latter	is	derived	from	the	amount	that	LDLc	is	decreased	in	mg/dl	using	
the	‘rule	of	thumb’	that	for	each	39mg/dl	(1.0mmol/l)	fall	in	LDLc	there	is	22%	decrement	in	risk	(9,	
33,45).	For	example,	both	alirocumab	and	evolocumab	consistently	lower	LDLc	by	60	%	on	average	
(regardless	of	initial	level).	If	the	starting	LDLc	(on	statin)	is	130	mg/dl	then	this	translates	into	a	
78mg/dl	(2.0mmol/l)	drop	which	in	turn	provides	a	44%	decrease	in	CVD	risk,	and	a	potentially	large	
absolute	risk	reduction.	If,	however,	the	starting	LDLc	is	75mg/dl	then	the	relative	risk	reduction	is	
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only	about	25%,	and	the	decrement	in	absolute	risk	proportionately	less.			(The	commonly	used	term	
‘NNT’	-	the	number-needed-to-treat	-	is	the	reciprocal	of	the	absolute	risk	reduction	and	hence	
provides	equivalent	information	(64)).	Thus,	NICE,	the	UK	body	which	rules	on	the	acceptability	of	
new	agents,	mandated	the	use	of	PCSK9	inhibitors	for	those	with	high	background	risk	–	poly-
vascular	disease,	multiple	past	CHD	events	–	and	elevated	LDLc	on	maximum	tolerated	statin	
therapy	(65).	A	similar	approach	has	been	recommended	in	updated	guidance	from	the	ACC	Task	
Force	(66)	and	the	ESC/	EAS	Task	Force	(67).	
	
A	strategy	for	profound	LDLc	lowering	that	takes	into	account	the	economic	realities	should	
therefore	be	based	on	risk	stratification	of	the	patient	and	an	estimate	of	the	benefit	that	would	
accompany	the	institution	of	combined	lipid	lowering	treatment	with	a	statin	and	ezetimibe	first	and	
then	addition	of	a	PCSK9	inhibitor	(Figure	3)	(66,67).	Formal	risk	stratification	schemes	have	been	
devised	for	acute	coronary	syndrome	patients	from	data	such	as	that	from	IMPROVE-IT	(68)	but	
more	work	is	needed	in	this	area	to	allow	better	targeting	of	therapy.	In	this	setting,	it	is	unlikely	
that	primary	prevention	subjects	with	the	exception	of	those	with	severe	FH	(64-67)	will	experience	
enough	of	an	absolute	reduction	in	CVD	risk	to	justify	adding	a	PCSK9	inhibitor	to	a	statin/ezetimibe	
regimen.		
	
Implications	and	implementation	of	profound	LDL	lowering	paradigm.	
	
Treatment	targets:	An	important	question	that	arises	from	recent	trial	results	is	‘If	a	treatment	goal	
for	all	secondary	prevention/	high	risk	patients	is	to	be	used,	should	it	now	be	set	at	a	lower	value?’	
Targets	for	intervention	are	at	best	an	artificial	and	idealised	construct	recommended	by	expert	
committees	as	a	useful	metric	of	therapeutic	success	(4,27).	The	monotonous	relationship	between	
LDL	(or	apoB-containing	lipoproteins)	and	CVD	risk	that	continues	down	to	sub-physiological	levels,	
and	indeed	virtually	to	zero	(Figure	2)	indicates	that	targets	if	they	are	employed	are	more	a	
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reflection	of	‘willingness	to	intervene’	rather	than	pathophysiologically	derived	landmarks.	
International	guidelines	agree	on	the	need	for	a	>50%	reduction	in	LDLc	relative	to	off-treatment	
levels	(3,4)	and	currently	European	and	Canadian	societies	continue	to	recommend	a	target	of	
<70mg/dl	(4,27).	Others	have	introduced	<50mg/dl	as	a	goal	when	risk	is	extremely	high	(69).	This	is	
a	continuing	topic	of	debate	–	should	we	have	a	more	aggressive	target	that	reflects	the	underlying	
pathology	but	creates	a	greater	unmet	need,	or	should	we	maintain	<70mg/dl	(in	countries	where	it	
is	recommended)	and	now	ensure	that	the	majority	rather	than	a	minority	are	able	to	reach	this	
level	with	a	combination	of	agents.	
	
Measurement	issues:	There	are	a	number	of	approaches	to	the	laboratory	assessment	of	LDLc	
concentration	in	the	circulation.		‘Beta-quantification’	which	uses	centrifugation	and	precipitation	to	
separate	lipoprotein	classes	physically	is	the	reference	method.	Direct	LDLc	tests,	and	the	
Friedewald	calculation	(based	on	knowing	total	plasma	cholesterol	and	triglyceride	and	HDL	
cholesterol)	are	convenient,	relatively	inexpensive,	and	provide	accurate	measurements	at	normal	
and	high	levels	(in	the	range	70	to	300	mg/dl).	However,	accuracy	of	the	Friedewald	equation	falls	
off	when	triglyceride	is	elevated	or	LDLc	is	low	(<70mg/dl)	(56).	Thus,	for	patients	on	combination	
lipid	lowering	treatment,	the	laboratory	reported	LDLc	may	be	lower	than	the	‘true’	concentration	
(56).	An	alternative,	more	robust	approach	is	to	measure	non-HDL	cholesterol	(total	minus	HDL)	or	
apolipoprotein	B	levels	that	capture	all	atherogenic	lipoproteins	and	these	parameters	are	promoted	
in	guidelines	and	expert	opinion	(4,27,	50,70).	The	apoB-containing	lipoprotein	species	within	‘non-
HDL	cholesterol’	include,	in	addition	to	LDL,	lipoprotein(a)	and	the	cholesterol	enriched	‘remnants’	
of	triglyceride-transporting	chylomicrons	and	very	low	density	lipoproteins.	Recent	evidence	has	
linked	both	lipoprotein(a)	(71)	and	remnants	(72)	to	increased	risk	of	cardiovascular	disease.	
Assessment	of	non-HDL	cholesterol	or	apoB	when	LDLc	has	been	lowered	profoundly	with	say	a	
PCSK9	inhibitor	may	help	reassure	the	patient	that	there	is	still	a	sufficiency	of	lipoproteins	present	
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to	perform	the	required	metabolic	transport	tasks	(the	decrease	in	these	variables	is	less	than	that	
seen	for	LDLc	(12,34,35)),	and	may	be	a	better	marker	of	ongoing	risk	(70).	
	
Patient	prioritization:	Profound	LDLc	lowering	is	most	likely	to	be	needed	in	patients	with	
established	disease,	either	those	who	have	had	an	event,	or	those	with	advanced	plaque	present	on	
imaging.	As	noted	above,	risk	stratification	in	secondary	prevention	needs	to	be	improved	but	at	
present	those	with	stable	disease	could	be	managed	with	high	intensity	statin,	or	increasingly	a	
combination	of	statin	plus	ezetimibe	to	achieve	a	50%	LDLc	decrease	and	a	level	<70mg/dl.	A	
‘highest	risk-highest	benefit’	approach	for	patients	with	an	aggressive	disease	course	is	a	useful	
strategy	for	deciding	when	to	add	a	PCSK9	inhibitor	(64-67,73).	In	such	patients,	the	high	risk	and	
elevated	LDLc	level	on	optimised	statin	therapy	provides	a	substantial	absolute	risk	reduction	(low	
NNT)	and	satisfactory	cost-effectiveness.	The	updated	2017	ESC/EAS	guidelines	set	out	thresholds	of	
140mg/dl	for	PCSK9	inhibitor	initiation	in	patients	with	clinical	atherosclerotic	CVD	and	100mg/dl	in	
those	severe,	aggressive	disease	(67)	(Figure	3).	Once	the	decision	has	been	made	to	add	a	PCSK9	
inhibitor	there	is,	according	to	the	emerging	paradigm,	no	target	and	neither	is	there	a	concern	that	
the	LDLc	is	too	low.	Data	from	trials	indicate	that	the	majority	treated	with	this	combination	will	
have	LDLc	below	50mg/dl	given	the	potency	of	the	agents.	In	conclusion,	in	light	of	this	emerging	
consensus	on	the	most	appropriate	strategy	for	further	LDLc	lowering	in	very	high	risk	patients,	the	
pressing	need	now		is	to	move	to	implementation.	
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Figure	legends	
	
Figure	1.	Context	and	rationale	for	LDL	lowering	strategies.	
The	schematic	depicts	the	change	in	LDL	cholesterol	over	a	life	course	in	males	(adapted	from	
reference	19;	for	females,	the	rise	in	adulthood	is	largely	delayed	until	the	menopause).	LDLc	in	
familial	hypercholesterolemia	is	elevated	from	birth	and	those	with	this	condition	have	an	enhanced	
integrated	LDL	exposure	(‘LDLc	x	years’)	and	early	atherosclerotic	CVD	(18).	The	risk	reduction	
associated	with	a	decrement	in	LDLc	is	predicted	to	be	greater	if	an	intervention	to	lower	this	
lipoprotein	is	initiated	earlier	(21).	It	is	speculated	that	this	is	due	to	the	nature	of	the	lesions	
present	across	the	decades	of	life.	The	risk	reductions	relative	to	LDL	lowering	are	extrapolated	from	
reference	21.	
	
Figure	2.	Association	of	achieved	LDLc	with	CVD	risk	in	lipid	lowering	trials.	
Figure	2A	(adapted	from	reference	14)	shows	for	trials	of	statin	versus	placebo,	or	more	vs	less	
intense	statin	treatment,	achieved	LDLc	in	the	two	arms	of	the	study	(linked	by	solid	bar)	and	
observed	ongoing	risk	of	a	coronary	event	(fatal	CHD	plus	non-fatal	myocardial	infarction).	The	
vertical	axes	are	adjusted	to	allow	primary	and	secondary	prevention	studies	to	be	examined	
together.	
Figure	2B	is	taken	from	the	FOURIER	trial	(reference	37	supplementary	data).	It	shows	for	all	
subjects	(i.e.	in	both	treatment	arms)	grouped	into	5	categories	of	increasing	LDLc	the	relationship	
between	mean	achieved	LDLc	and	event	rate.	The	association	is	monotonous	(P<0.001	for	trend)	
with	no	attenuation	at	even	very	low	LDLc.	The	sub-group	of	lowest	LDLc	(<10mg/dl)	is	also	
depicted;	it	had	a	commensurately	low	CVD	risk.	
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Figure	3.	Therapeutic	strategies	for	profound	LDL	lowering.	
This	flowchart	is	illustrative	of	developing	paradigms	of	combination	lipid-lowering	therapy	
(presented	in	much	greater	detail	in	references	66,67).	It	is	envisaged	that	many	patients	with	
atherosclerotic	vascular	disease	(ASCVD)	will	require	up-titration	of	their	statin	dose	to	achieve	
guideline	targets	where	these	are	recommended	(e.g.	in	European/	Canadian	guidelines	4,	27).	
There	is	a	limit	to	what	can	be	achieved	with	high	intensity	statin	therapy.	The	need	for	further	LDL	
lowering	(and	possibly	patient	preference)	leads	to	routine	addition	of	ezetimibe	(51,66,67).	Where	
there	is	a	predicted	very	high	CVD	risk	and	an	elevated	LDLc	then	a	PCSK9	inhibitor	can	be	
considered	(64-67,73).	Here	the	goal	is	to	achieve	a	substantial	absolute	risk	reduction	(low	NNT)	
personalized	for	the	patient	and	acceptable	to	the	payer.	Annual	risks	(%/y)	are	quoted	for	
illustrative	purposes	only;	more	detail	on	the	type	of	CVD	patient	that	will	reach	an	appropriate	risk	
threshold	is	given	in	references	64-67.	 	
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Figure	2	
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Figure	3	
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